Di Scala, C.; Armstrong, N.; Chahinian, H.; Chabrière, E.; Fantini, J.; Yahi, N.
AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery. Int. J. Mol. Sci. 2022, 23, 13383.
https://doi.org/10.3390/ijms232113383
AMA Style
Di Scala C, Armstrong N, Chahinian H, Chabrière E, Fantini J, Yahi N.
AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery. International Journal of Molecular Sciences. 2022; 23(21):13383.
https://doi.org/10.3390/ijms232113383
Chicago/Turabian Style
Di Scala, Coralie, Nicholas Armstrong, Henri Chahinian, Eric Chabrière, Jacques Fantini, and Nouara Yahi.
2022. "AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery" International Journal of Molecular Sciences 23, no. 21: 13383.
https://doi.org/10.3390/ijms232113383
APA Style
Di Scala, C., Armstrong, N., Chahinian, H., Chabrière, E., Fantini, J., & Yahi, N.
(2022). AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery. International Journal of Molecular Sciences, 23(21), 13383.
https://doi.org/10.3390/ijms232113383
